27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Shares of biotech Chembio Diagnostics Inc (NASDAQ: CEMI) got a dramatic boost in the arm Monday morning.
The Medford, New York-based firm announced a partnership with Integrated BioTherapeutics, Inc to develop and continue to maintain "exclusive rights to any POC (Point of Care) product developed through (their) agreement."
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Chembio will combine its patented DPP(R) technology with IBT's proprietary Ebola reagents to develop POC diagnostic tests for Ebola and febrile illness.
At time of writing, shres were trading at a robust pace. Volume was up over 600 percent, when compared to Chembio's average three-month trading volume.
The stock was recently up 14.5 percent at $4.56, from previous close of $3.99 per share.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.